SPRY ARS Pharmaceuticals
- 8.350
- +0.260+3.21%
- 8.270
- -0.080-0.96%
ARS Pharmaceuticals News
Insider Trading: ARS Pharmaceuticals' (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ARS Pharmaceuticals, Inc., a biopharmaceutica
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
Richard E Lowenthal, 10% Owner, Director, PRESIDENT AND CEO, on April 16, 2024, sold 100,000 shares in ARS Pharmaceuticals (SPRY) for $928,005. Following the Form 4 filing with the SEC, Lowenthal has
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$928.01K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on Apr 16, 2024 at an average price of $9.2801 for a total value of $928.01K. This transaction invol
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$927.73K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on Apr 9, 2024 at an average price of $9.2773 for a total value of $927.73K. This transaction involv
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing
Richard E Lowenthal, 10% Owner, Director, President and CEO, on April 09, 2024, sold 100,000 shares in Ars Pharmaceuticals (SPRY) for $927,735. Following the Form 4 filing with the SEC, Lowenthal has
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
ARS Pharmaceuticals Responded to FDA CRL for Epinephrine Nasal Spray
Express News | ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For Neffy
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicat
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Buys US$13.29 Million in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder RA CAPITAL MANAGEMENT, L.P. purchased 1.4 million shares of Common Stock on Mar 25, 26, 27, 2024 at an average price of $9.48 for a total value of $13.29
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$890.32K in Common Stocks
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Tanimoto Sarina sold 97,610 shares of Common Stocks on Mar 22, 25, 2024 at an average price of $9.1212 for a total value of $890.32K. This transaction in
Buy Rating on ARS Pharmaceuticals Amid Strong Neffy Approval Prospects and Indication Expansion
Ars Pharmaceuticals' Merger May Limit Use of Net Operating Losses, Impacting Future Financials
Express News | CORRECTION: On Thursday March 21, 2024 ARS Pharmaceuticals Reported Q4 EPS $(0.07) Beats $(0.14) Estimate
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$21,572.06 in Common Stocks
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Tanimoto Sarina sold 2,390 shares of Common Stocks on Mar 19, 21, 2024 at an average price of $9.026 for a total value of $21,572.06. This transaction in
ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results
Express News | ARS Pharmaceuticals Q4 2023 GAAP EPS $(0.57) Misses $(0.14) Estimate
ARS Pharmaceuticals 4Q Loss $7.2M >SPRY
ARS Pharmaceuticals 4Q Loss $7.2M >SPRY
Analysis
Price Target
No Data
